Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease

Movement Disorders

Volumn 29, Issue 4, 2014, Pages 518-526

  Abbott, Sarah K ^a   Li, Hongyun ^a   Muñoz, Sonia Sanz ^a   Knoch, Bianca ^a   Batterham, Marijka ^a   Murphy, Karen E ^b,c   Halliday, Glenda M ^b,c   Garner, Brett ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Ceramide; Ceramide synthase genes; Parkinson's disease; Postmortem tissue analysis; Sphingolipidomics; Sphingomyelin

Indexed keywords

MESSENGER RNA; SPHINGOMYELIN; CERAMIDE; DIHYDROCERAMIDE DESATURASE; OXIDOREDUCTASE;

ANTERIOR CINGULATE; ARTICLE; BRAIN TISSUE; CERAMIDE ACYLCHAIN GENE; CERAMIDE SYNTHASE GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; OCCIPITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; AGED; BRAIN; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN; CERAMIDES; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PARKINSON DISEASE;

EID: 84898057274     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25729     Document Type: Article

References (51)

1. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
2. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010;16:653-661.
3. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
4. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 2000;166:324-333.
5. Halliday GM, Ophof A, Broe M, et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005;128:2654-2664.
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
7. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S1-S5.
8. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-195.
9. Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM. ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 2013;1:11.
10. Bras J, Singleton A, Cookson MR, Hardy J. Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008;275:5767-5773.
11. Haughey NJ. Sphingolipids in neurodegeneration. Neuromolecular Med 2010;12:301-305.
12. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010;1801:878-886.
13. Fabelo N, Martin V, Santpere G, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med 2011;17:1107-1118.
14. Zhao L, Spassieva SD, Jucius TJ, et al. A deficiency of ceramide biosynthesis causes cerebellar Purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genet 2011;7:e1002063.
15. Grösch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res 2012;51:50-62.
16. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643-665.
17. Silva LC, Ben David O, Pewzner-Jung Y, et al. Ablation of ceramide synthase 2 strongly affects biophysical properties of membranes. J Lipid Res 2012;53:430-436.
18. Morales A, Lee H, Goñi F, Kolesnick R, Fernandez-Checa J. Sphingolipids and cell death. Apoptosis 2007;12:923-939.
19. Movsesyan VA, Yakovlev AG, Dabaghyan EA, Stoica BA, Faden AI. Ceramide induces neuronal apoptosis through the caspase-9/caspase-3 pathway. Biochem Biophys Res Commun 2002;299:201-207.
20. Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 2005;118:4605-4612.
21. Mencarelli C, Martinez-Martinez P. Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 2013;70:181-203.
22. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 2008;20:1010-1018.
23. Gillard BK, Clement RG, Marcus DM. Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways. Glycobiology 1998;8:885-890.
24. Tettamanti G, Bassi R, Viani P, Riboni L. Salvage pathways in glycosphingolipid metabolism. Biochimie 2003;85:423-437.
25. Soreghan B, Thomas SN, Yang AJ. Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration. Adv Drug Deliv Rev 2003;55:1515-1524.
26. DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord 2009;24:1571-1578.
27. Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009;66:571-576.
28. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
29. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72:455-463.
30. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
31. Ben-David O, Futerman AH. The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular Med 2010;12:341-350.
32. Levy M, Futerman AH. Mammalian ceramide synthases. IUBMB Life 2010;62:347-356.
33. Lue LF, Walker DG, Adler CH, et al. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol 2012;22:745-756.
34. Zhou J, Broe M, Huang Y, et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol 2011;121:695-704.
35. Halliday G, Ng T, Rodriguez M, et al. Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol 2002;104:72-78.
36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
37. Abbott SK, Jenner AM, Mitchell TW, Brown SH, Halliday GM, Garner B. An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids 2013;48:307-318.
38. Ejsing CS, Duchoslav E, Sampaio J, et al. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem 2006;78:6202-6214.
39. Cheng D, Jenner AM, Shui G, et al. Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One 2011;6:e17299.
40. Li H, Evin G, Hill AF, Hung YH, Bush AI, Garner B. Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. Clin Sci (Lond) 2012;122:409-419.
41. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
42. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available at: http://www.R-project.org. Accessed October 17, 2013.
43. Laviad EL, Albee L, Pankova-Kholmyansky I, et al. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 2008;283:5677-5684.
44. Manning-Bog AB, Schule B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009;30:1127-1132.
45. Lei X, Zhang S, Bohrer A, Bao S, Song H, Ramanadham S. The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase. Biochemistry 2007;46:10170-10185.
46. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005;102:18676-18681.
47. Darios F, Corti O, Lucking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 2003;12:517-526.
48. Sassa T, Suto S, Okayasu Y, Kihara A. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells. Biochim Biophys Acta 2012;1821:1031-1037.
49. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004;24:6715-6723.
50. Jana A, Hogan EL, Pahan K. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 2009;278:5-15.
51. Zigdon H, Kogot-Levin A, Park JW, et al. Ablation of ceramide synthase 2 causes chronic oxidative stress due to disruption of the mitochondrial respiratory chain. J Biol Chem 2013;288:4947-4956.